China Universal Asset Management Company’s Nektar Therapeutics NKTR Stock Holding History

China Universal Asset Management Company’s Portfolio NKTR Stock Details NKTR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$112K	Sell	1,600 -2,400	-60%	-$176K	0.01%	408
2026 Q1	$288K	Buy	+4,000	New	+$228K	0.02%	318
2023 Q4	–	Sell	-325	Closed	-$2.91K	–	465
2023 Q3	$2.91K	Buy	325 +160	+97%	+$1.54K	﹤0.01%	417
2023 Q2	$1.43K	Sell	165 -6	-4%	-$64	﹤0.01%	442
2023 Q1	$1.8K	Buy	171 +44	+35%	+$1.33K	﹤0.01%	434
2022 Q4	$4.32K	Buy	127 +10	+9%	+$484	﹤0.01%	312
2022 Q3	$6K	Buy	+117	New	+$6.96K	﹤0.01%	258

Other funds holding NKTR

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Two Seas Capital Rye, New York $8.68B AUM 78.08% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

China Universal Asset Management Company's NKTR Position: Q2 2026 in Review

China Universal Asset Management Company reduced its Nektar Therapeutics (NKTR) stake by 60% in Q2 2026, selling an estimated $176K and leaving 1,600 shares worth $112K. The position accounts for 0.01% of the portfolio, ranked #408.

China Universal Asset Management Company first reported a position in NKTR in Q3 2022 and has held it in 7 quarters since. The position peaked at $288K in Q1 2026. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

China Universal Asset Management Company held 1,600 shares of Nektar Therapeutics worth $112K as of Q2 2026.
China Universal Asset Management Company sold 2,400 Nektar Therapeutics shares in Q2 2026, an estimated $176K.
Nektar Therapeutics made up 0.01% of China Universal Asset Management Company's portfolio in Q2 2026, its #408 holding.
China Universal Asset Management Company first reported a position in Nektar Therapeutics in Q3 2022 and has held it in 7 quarters since.
China Universal Asset Management Company's Nektar Therapeutics position peaked at $288K in Q1 2026.
239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on China Universal Asset Management Company's 13F filing for Q2 2026, filed 24 Jul 2026.